For the long term holders, I would like to point out that...

For the long term holders, I would like to point out that Merck's multi billion dollar cancer immunology drug Keytruda also had a number of clinical set backs.. some very recent including the ph3 trial treating small-cell lung cancer last month, ph3 trials treating multiple melanoma, and a late-stage breast cancer trial last year. Although Keytruda is a completely different drug, my view is that efti was also destined to come across a number of mixed results with its studies as it is not the cure-all drug. Unfortunately this result pushed back the finish line in terms of commercialisation, but I think it once again validated the effectiveness of efti on cancer patients. Luckily we're not a one trick pony and have a few fully funded studies ongoing which I hope will bring us more positive results. If you're a long term holder, good luck to us all!